Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie.
Adverse events may also be reported to Bristol-Myers Squibb via firstname.lastname@example.org or 0800 731 1736 (UK); 1 800 749 749 (Ireland).
If you require any further information regarding the use of apixaban, please contact
When reporting, please provide as much information as possible, including information on medical history, any concomitant medication, onset and treatment dates.